-
公开(公告)号:US20220395586A1
公开(公告)日:2022-12-15
申请号:US17816139
申请日:2022-07-29
Applicant: Genzyme Corporation
Inventor: Lisa M. STANEK , Lamya S. SHIHABUDDIN
Abstract: Provided herein are novel methods for delivering recombinant adeno-associated viral (rAAV) particles to the central nervous system of a mammal (e.g., a human). In aspects, the methods involve administering rAAV particles containing a heterologous nucleic acid to the striatum and causing expression of the heterologous nucleic acid in at least the cerebral cortex and the striatum of the mammal.
-
公开(公告)号:US20210047641A1
公开(公告)日:2021-02-18
申请号:US16941303
申请日:2020-07-28
Applicant: Genzyme Corporation
Inventor: Lisa M. STANEK , Adam PALERMO , Brenda RICHARDS , Sergio Pablo SARDI , Catherine O'RIORDAN , Antonius SONG
IPC: C12N15/113
Abstract: Provided herein are RNAi molecules including a first strand containing a guide sequence and a second strand comprising a non-guide sequence where the non-guide sequence contains a bulge opposite the seed region of the guide sequences; e.g., opposite the cleavage sequence. In some aspects, the invention provides RNAi for treating Huntington's disease. Further provided herein are expression cassettes, vectors (e.g., rAAV, recombinant adenoviral, recombinant lentiviral, and recombinant HSV vectors), cells, viral particles, and pharmaceutical compositions containing the RNAi. Yet further provided herein are methods and kits related to the use of the RNAi, for example, to treat Huntington's disease.
-
公开(公告)号:US20210189430A1
公开(公告)日:2021-06-24
申请号:US17194009
申请日:2021-03-05
Applicant: Genzyme Corporation
Inventor: Abraham SCARIA , Jennifer SULLIVAN , Lisa M. STANEK , Lamya S. SHIHABUDDIN
IPC: C12N15/86 , A61K48/00 , C07K14/71 , C07K14/015 , C12N7/00 , C12N15/113
Abstract: Provided herein are improved rAAV (e.g., rAAV2, rAAVrh8R, etc.) for enhanced gene therapy of ocular disorders or CNS disorders wherein the rAAV comprise one or more substitutions of amino acids that interact with heparan sulfate proteoglycan. The invention provides methods for improved transduction of retinal cells and methods for treating ocular diseases with improved compositions of rAAV particles. Further provided herein are improved recombinant adeno-associated virus (rAAV) (e.g., rAAV2, rAAVrh8R, etc.) for enhanced gene therapy of disorders of the CNS. The invention provides methods for delivering the rAAV to the CNS, methods for treating disorders of the CNS with improved compositions of rAAV particles, and kits for delivering the rAAV to the CNS and/or treating a CNS disorder.
-
公开(公告)号:US20200216848A1
公开(公告)日:2020-07-09
申请号:US16649042
申请日:2018-09-21
Applicant: Genzyme Corporation
Inventor: Catherine R. O'RIORDAN , Adam PALERMO , Brenda RICHARDS , Lisa M. STANEK
IPC: C12N15/113 , C12N7/00 , C12N15/86 , A61K35/761 , A61P25/28
Abstract: Provided herein are RNAi molecules for treating Huntington's disease. Further provided herein are expression cassettes, vectors (e.g., rAAV, recombinant adenoviral, recombinant lentiviral, and recombinant HSV vectors), cells, viral particles, and pharmaceutical compositions containing the RNAi. Yet further provided herein are methods and kits related to the use of the RNAi, for example, to treat Huntington's disease.
-
公开(公告)号:US20200109401A1
公开(公告)日:2020-04-09
申请号:US16566565
申请日:2019-09-10
Applicant: Genzyme Corporation
Inventor: Lisa M. STANEK , Adam PALERMO , Brenda RICHARDS , Sergio Pablo SARDI , Catherine O'RIORDAN , Antonius SONG
IPC: C12N15/113
Abstract: Provided herein are RNAi molecules including a first strand containing a guide sequence and a second strand comprising a non-guide sequence where the non-guide sequence contains a bulge opposite the seed region of the guide sequences; e.g., opposite the cleavage sequence. In some aspects, the invention provides RNAi for treating Huntington's disease. Further provided herein are expression cassettes, vectors (e.g., rAAV, recombinant adenoviral, recombinant lentiviral, and recombinant HSV vectors), cells, viral particles, and pharmaceutical compositions containing the RNAi. Yet further provided herein are methods and kits related to the use of the RNAi, for example, to treat Huntington's disease.
-
公开(公告)号:US20170096683A1
公开(公告)日:2017-04-06
申请号:US15308335
申请日:2015-05-02
Applicant: Genzyme Corporation
Inventor: Abraham SCARIA , Jennifer SULLIVAN , Lisa M. STANEK
IPC: C12N15/86 , C12N15/113 , A61K48/00 , C12N7/00
CPC classification number: C12N15/86 , A61K48/0075 , C07K14/015 , C07K14/71 , C12N7/00 , C12N15/113 , C12N2310/141 , C12N2320/32 , C12N2750/14122 , C12N2750/14143 , C12N2750/14145
Abstract: Provided herein are improved rAAV (e.g., rAAV2, rAAVrh8R, etc.) for enhanced gene therapy of ocular disorders or CNS disorders wherein the rAAV comprise one or more substitutions of amino acids that interact with heparan sulfate proteoglycan. The invention provides methods for improved transduction of retinal cells and methods for treating ocular diseases with improved compositions of rAAV particles. Further provided herein are improved recombinant adeno-associated virus (rAAV) (e.g., rAAV2, rAAVrh8R, etc.) for enhanced gene therapy of disorders of the CNS. The invention provides methods for delivering the rAAV to the CNS, methods for treating disorders of the CNS with improved compositions of rAAV particles, and kits for delivering the rAAV to the CNS and/or treating a CNS disorder.
-
公开(公告)号:US20240182896A1
公开(公告)日:2024-06-06
申请号:US18483474
申请日:2023-10-09
Applicant: Genzyme Corporation
Inventor: Lisa M. STANEK , Adam PALERMO , Brenda RICHARDS , Sergio Pablo SARDI , Catherine O'RIORDAN , Antonius SONG
IPC: C12N15/113
CPC classification number: C12N15/113 , C12N2310/14 , C12N2310/531 , C12N2310/533
Abstract: Provided herein are RNAi molecules including a first strand containing a guide sequence and a second strand comprising a non-guide sequence where the non-guide sequence contains a bulge opposite the seed region of the guide sequences; e.g., opposite the cleavage sequence. In some aspects, the invention provides RNAi for treating Huntington's disease. Further provided herein are expression cassettes, vectors (e.g., rAAV, recombinant adenoviral, recombinant lentiviral, and recombinant HSV vectors), cells, viral particles, and pharmaceutical compositions containing the RNAi. Yet further provided herein are methods and kits related to the use of the RNAi, for example, to treat Huntington's disease.
-
公开(公告)号:US20190111157A1
公开(公告)日:2019-04-18
申请号:US15549962
申请日:2016-02-09
Applicant: Genzyme Corporation
Inventor: Lisa M. STANEK , Lamya SHIHABUDDIN
Abstract: Provided herein are novel methods for delivering recombinant adeno-associated viral (rAAV) particles to the central nervous system of a mammal (e.g., a human). In aspects, the methods involve administering rAAV particles containing a heterologous nucleic acid to the striatum and causing expression of the heterologous nucleic acid in at least the cerebral cortex and the striatum of the mammal.
-
公开(公告)号:US20180023082A1
公开(公告)日:2018-01-25
申请号:US15549895
申请日:2016-02-09
Applicant: Genzyme Corporation
Inventor: Lisa M. STANEK , Adam PALERMO , Brenda RICHARDS , Sergio Pablo SARDI , Catherine O'RIORDAN , Antonius SONG
IPC: C12N15/113
Abstract: Provided herein are RNAi molecules including a first strand containing a guide sequence and a second strand comprising a non-guide sequence where the non-guide sequence contains a bulge opposite the seed region of the guide sequences; e.g., opposite the cleavage sequence. In some aspects, the invention provides RNAi for treating Huntington's disease. Further provided herein are expression cassettes, vectors (e.g., rAAV, recombinant adenoviral, recombinant lentiviral, and recombinant HSV vectors), cells, viral particles, and pharmaceutical compositions containing the RNAi. Yet further provided herein are methods and kits related to the use of the RNAi, for example, to treat Huntington's disease.
-
-
-
-
-
-
-
-